<DOC>
	<DOCNO>NCT01662336</DOCNO>
	<brief_summary>The study ass effectiveness KASA ( Kaletra Patient Support Program ) improve maintain treatment adherence HIV positive patient initiate treatment Kaletra® . This purely observational study conduct patient treatment Kaletra® . All treatment per routine care include use KASA determine exclusively physician patient without consideration study . The efficacy disease management program assess randomized clinical trial representative real - life effectiveness observe routine clinical practice . In real - life setting utilization compliance disease management program physicians patient uniform . Therefore assessment true effectiveness ideally conduct pure observational setting without interference investigator respect make program available patient enforce adherence .</brief_summary>
	<brief_title>Real-life Effectiveness Kaletra Adherence Support Assistance ( KASA ) Program</brief_title>
	<detailed_description>This 12-month , multi-center , Canadian Post Marketing Observational Study utilize prospective single cohort design . Patients treat Kaletra® include initiated treatment Kaletra® eligible participate . All treatment include participation KASA ( Kaletra Adherence Support Assistance ) program accord decision treat physician patient affect way decision participate study . Follow-up 12 month visit conduct accord physician judgment . However , assessment every six month recommend .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<criteria>Subject HIV+ ( positive Human Immunodeficiency Virus ) On treatment Kaletra® currently initiate treatment Kaletra® . Has provide write informed consent allow use data study provide permission contact study personnel . Willing enrolled Kaletra Adherence Support Assistance ( KASA ) program . Not willing sign inform consent . In opinion treat physician unlikely available 12month followup duration study . Is currently participate clinical trial investigational product . Not willing participate KASA program .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Human Immunodeficiency Virus infection</keyword>
</DOC>